WHO announces resumption of experiments with hydroxychloroquine

The World Health Organization announced on Wednesday that it has resumed the test for hydroxychloroquine, after shutting it down after the publication of a study in the medical journal ‘The Lancet’.

The World Health Organization (WHO) announced on Wednesday, June 3, the resumption of clinical trials on hydroxychloroquine, nine days after interrupting them following the publication of a study in the prestigious medical journal ‘The Lancet’.

In late April, WHO initiated clinical trials, especially on hydroxychloroquine, called “Solidarity”, in order to find effective treatment against Covid-19.

On May 25, the World Health Authority announced the suspension of trials with hydroxychloroquine following the publication of a study in the medical journal The Lancet which considered ineffective or even harmful to the use of chloroquine or its derivatives, e.g. hydroxychloroquine against Covid-19.

>> Also read:In the press – “Chloroquine, pills without a future?”

The interruption of the trials was to allow WHO to analyze available information and a decision was expected in mid-June.

But when The Lancet distanced itself from the study on Tuesday night and acknowledged in a formal warning that “important issues” were hovering over it, the WHO released its findings earlier than expected.

No differences noted “in mortality”

“We are now pretty sure we have not seen any differences in mortality,” Soumya Swaminathan, WHO’s chief scientist, said Wednesday during a virtual press conference from the Geneva headquarters for organization.

After analyzing the “available mortality data”, members of the Security and Monitoring Committee “felt that there was no reason to change the protocol[des essais cliniques]”, WHO Director General Tedros Adhanom Ghebreyesus insisted during a virtual press conference.

A great global study

The Solidarity Investigation Executive Group, which represents participating countries, “received this recommendation and approved the continuation of all dimensions of the trials, including hydroxychloroquine,” he said.

“The executive team will communicate with the key researchers responsible for the trial regarding the reintroduction of the hydroxychloroquine dimension in the trial,” he said.

>> See also:Covid-19 Pandemic: The race for treatments and vaccines is accelerating

The study was published in The Lancet on May 22 and is based on data from 96,000 patients admitted between December and April in 671 hospitals, comparing the status of those who received treatment with those patients who did not. Had not.

With AFP